AIDS Funding At Inflection Point As Spending By Recipients Outpaces Donors
This article was originally published in PharmAsia News
Increases in spending by local governments will not decrease the need for international funding, but the fading political will to continue support in U.S. and other donor countries is worrisome, former Global Fund director says.
You may also be interested in...
Far from energizing the ‘march-in’ debate, the GAO study finds limited potential impact, but a new antitrust clause in licensing agreements could give companies something to worry about even if specter of government pricing setting might not be a big concern. Even though GAO found that NIH-licensed products amount to about 1% of government drug spend, the issue isn’t likely to disappear because Biden will face continued pressure to act on drug pricing and a Republican Senate gives him few options.
The first biosimilar with interchangeability status compared to its reference will be entitled to one year of exclusivity, a largely overlooked advantage in the early days of the US biosimilar market.
An early meeting option is needed so sponsors can discuss clinical trial endpoints and similar issues before analytic data is available, industry tells the US FDA.